Candida Species Nucleic Acid Detection System
PII is the FDA product code for Candida Species Nucleic Acid Detection System, a class II device type, regulated under 21 CFR 866.3960. FDA's definition for this code reads: "The Candida species nucleic acid detection system is a qualitative panel for the direct detection of Candida species in whole blood specimens from patients with symptoms of, or medical conditions predisposing the patients to, invasive fungal infections. The test is indicated for the presumptive diagnosis of...". As of , FDA records hold 3 510(k) clearances under this code, the most recent dated , and one recall.
Classification record
- Product code
- PII
- Device name
- Candida Species Nucleic Acid Detection System
- FDA definition
- The Candida species nucleic acid detection system is a qualitative panel for the direct detection of Candida species in whole blood specimens from patients with symptoms of, or medical conditions predisposing the patients to, invasive fungal infections. The test is indicated for the presumptive diagnosis of candidemia. The test is performed independent of blood culture. Concomitant blood cultures are necessary to recover organisms for susceptibility testing or further identification.
- Regulation
- 21 CFR 866.3960
- Device class
- Class II
- Review panel
- Microbiology
- Submission type
- 510(k)
- Implant
- No
- Life sustaining or supporting
- No
- GMP exempt
- No
- Third party review eligible
- No
- Ingested clearances
- 3
- Ingested recalls
- 1
Clearances, product code PII
By decision yearShow the numbers
| Year | Clearances |
|---|---|
| 2014 | 1 |
| 2017 | 1 |
| 2024 | 1 |
Applicants with the most clearances
Product code PII| Applicant | Clearances |
|---|---|
| T2biosystems, Inc. | 3 |
Companies listing this code with FDA
Companies whose registered establishments list this codeFIRST ARTICLE / WEEKLY
What cleared, what was recalled, and what changed in the standards. One edition a week for the people who make medical devices.
